Prophylactic and Therapeutic Antibodies
joint with Biology of B Cell Responses
Organizer(s): Margaret Karow and Neil StahlDate: February 09 - 14, 2014
Location: Keystone Resort, Keystone, CO, USA
Until recently, most antibody therapeutics have been indicated for inflammatory diseases and cancer. The success of this approach has led to an expansion to a broader group of diseases such as infection, metabolic diseases, pain, Alzheimer’s and bone diseases, bringing a new level of challenge. This meeting will address developing antibodies for prophylactic- or chronic-use indications that have traditionally been dominated by small-molecule therapeutics, with case studies describing the development of antibodies for these marketplaces. It will also explore how molecule choices, dosing and delivery, and clinical design for efficacy and the minimization of safety risk, all impact success. The meeting will address up-and-coming approaches such as antibody engineering for pharmacokinetic and pharmacodynamic improvements, the use of vaccines to induce humoral responses in vivo, and use of antibodies to deliver vaccines, as well as look back at what has been learned from chronic therapy of immune diseases. We expect the attendees will be from the fields of translational medicine, antibody generation, pre-clinical pharmacology and clinical testing, whose work contributes to and drives innovation in these fields. It is anticipated that they will come away with an appreciation of these challenges and that the meeting will stimulate research and novel solutions for addressing this group of indications. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on “Biology of B Cell Responses,” which will share a plenary session on antibody diversity.
Scholarship Deadline: October 16 2013
Discounted Abstract Deadline: October 16 2013
Abstract Deadline: November 14 2013
Discounted Registration Deadline: December 10 2013
We gratefully acknowledge additional support for this conference from:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Alexion Pharmaceuticals, Inc.
We gratefully acknowledge the generous grant for this conference provided by:National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI109807-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.